The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Postoperative ischaemia; Reperfusion injury
- Focus Pharmacodynamics
- 03 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 03 Nov 2016 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 03 Nov 2016 Status changed from active, no longer recruiting to recruiting.